NASDAQHealth CareBiotechnologySnapshot 2026-07-31
Reading ALNY? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar broken — Control R&D and SG&A expenses to $2.7B-$2.8B in 2026: metric not reported.
View ThesisManagement screens strong on capital allocation, margins.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 58% in its worst 12-month stretch.
View RiskAlnylam Pharmaceuticals must maintain its revenue growth to justify its current price. Revenue grew 67% year over year, and the last quarter beat expectations. It trades at 26× P/E versus a peer median of 20×. This suggests the price reflects less growth than anticipated. A specific risk is the forecasted revenue falling below management's target range. Peer multiples imply a price about 17% above where it trades; this read is provisional.
Trailing returns as of 2026-07-31. ALNY is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 29 analysts currently covering ALNY (as of Jul 2026).
Based on 8 Wall Street analysts offering 12-month price targets for ALNY in the last 4 months.
A consensus fair price across 7 valuation methods, at three horizons. As of 2026-08-01. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Threatens: Achieve $4.2B-$4.5B total TTR net product revenues in 2026
TTR guidance cut impacts revenue growth expectations.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-31. EPS is implied from price ÷ P/E. Not investment advice.
Current $205.52
The last 12 months of price, then the range of analyst 12-month targets from today’s $205.52.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Around the middle on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Threatens: Achieve $4.9B-$5.3B revenue in 2026
Forecasted revenue below management's target range.
Advances: Expand TTR Franchise revenues to $2.475B-$2.525B
Commercial momentum supports TTR franchise revenue growth.
Threatens: Expand TTR Franchise revenues to $2.475B-$2.525B
Price target cut reflects concerns about TTR Franchise growth.
Rival trial failure may impact market dynamics and competitive landscape.
Rival's failure enhances Alnylam's competitive position.
Partnership expansion supports revenue growth objectives.
Lower price target indicates potential revenue concerns.
